Stoke and Biogen to present Zorevunersen clinical data at EEC
Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.